AIDS WEEKLY Plus - June 2004Important note: Information in this article was accurate in June 2004. The state of the art may have changed since the publication date.
Click here to return to AIDS WEEKLY PLUS main menu

DonateNow
Print this Article

HIV/AIDS: Ezrin/CD95 linkage key role regulating susceptibility to CD95-mediated apoptosis

AIDSWEEKLY Plus; Monday, June 21, 2004
Staff Medical Writers


NewsRx -- Ezrin/CD95 linkage has a key role regulating susceptibility to CD95-mediated apoptosis.

According to published research from Italy, "CD95(APO-1/Fas)-mediated apoptosis of bystander uninfected T cells exerts a major role in the HIV-1-mediated CD4+ T-cell depletion. HIV-1 gp120 has a key role in the induction of sensitivity of human lymphocytes to CD95-mediated apoptosis through its interaction with the CD4 receptor. Recently, we have shown the importance of CD95/ezrin/actin association in CD95-mediated apoptosis."

"In this study," reported F. Luciani and colleagues, "we explored the hypothesis that the gp120-mediated CD4 engagement could be involved in the induction of susceptibility of primary human T lymphocytes to CD95-mediated apoptosis through ezrin phosphorylation and ezrin-to-CD95 association."

Results demonstrate "that gp120/IL-2 combined stimuli, as well as the direct CD4 triggering, on human primary CD4+ T lymphocytes induced an early and stable ezrin activation through phosphorylation, consistent with the induction of ezrin/CD95 association and susceptibility to CD95- mediated apoptosis."

Luciani concluded, "Our results provide a new mechanism through which HIV-1-gp120 may predispose resting CD4+ T cell to bystander CD95-mediated apoptosis and support the key role of ezrin/CD95 linkage in regulating susceptibility to CD95-mediated apoptosis."

Luciani and colleagues published their findings in Cell Death and Differentiation (CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4+ T lymphocytes. Cell Death Differ. 2004 May;11(5):574-82.

Additional information can be obtained by contacting S. Fais, Ist Super Sanita, Immunology Laboratory, Viale Regina Elena 299, I-00161 Rome, Italy.

The publisher of the journal Cell Death and Differentiation can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.

The information in this article comes under the major subject areas of AIDS & HIV, Apoptosis, Immunology and Receptor Studies.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Luciani F, Matarrese P, Giammarioli AM, et al. "CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4(+)T lymphocytes", Cell Death Differ. 2004 May;11(5):574-82

PubMED Related articles Search

040621
AW040607


Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.